title: Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
abstract: OBJECTIVE
  To analyze the clinical role of hormone receptors in a large uterine sarcomas series with long-term follow-up.
  
  
  METHODS
  Protein expression of estrogen receptor (ER) and progesterone receptor (PR) by immunohistochemistry was studied in tissue microarrays from 294 patients diagnosed with uterine sarcoma in Norway from 1970 to 2000 and analyzed for an association with clinicopathologic parameters and outcome.
  
  
  RESULTS
  ER and PR were detected in 136 of 291 and 184 of 291 tumors (three noninformative cases each), respectively. Expression was unrelated to histology, patient age, tumor diameter, the degree of atypia, the presence of necrosis or vascular invasion, or mitotic counts. ER and PR expression was unrelated to survival in the analysis of the entire cohort. When survival analysis was confined to stage I leiomyosarcoma (n = 147), higher PR score was significantly related to longer overall survival (OS) (P = .042). Clinicopathologic prognosticators in this group were age (P = .041), tumor diameter (P = .001), and mitotic count (P = .007), with a trend for atypia (P = .087). In Cox multivariate analysis, PR score (P = .019), tumor diameter (P = .013), and mitotic count (P = .002) were independent prognosticators of OS.
  
  
  CONCLUSIONS
  Hormone receptor expression is not informative of outcome in the analysis of uterine sarcomas of all stages and histologic types. PR expression identifies patients with longer survival in stage I leiomyosarcoma.
authors.affiliation: From the Department of Pathology Institute for Clinical Medicine bend@medisin.uio.no.
authors.forename: Ben
authors.initials: B
authors.lastname: Davidson
authors.affiliation: Institute for Cancer Genetics and Informatics.
authors.forename: Marna Lill
authors.initials: ML
authors.lastname: Kjæreng
authors.affiliation: From the Department of Pathology.
authors.forename: Mette
authors.initials: M
authors.lastname: Førsund
authors.affiliation: Institute for Cancer Genetics and Informatics Center of Cancer Biomedicine Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, John Radcliffe Hospital, Headley Way, University of Oxford, Oxford, United Kingdom.
authors.forename: Håvard Emil
authors.initials: HE
authors.lastname: Danielsen
authors.affiliation: Department of Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Institute for Clinical Medicine.
authors.forename: Gunnar Balle
authors.initials: GB
authors.lastname: Kristensen
authors.affiliation: From the Department of Pathology.
authors.forename: Vera Maria
authors.initials: VM
authors.lastname: Abeler
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D007890:Leiomyosarcoma / Q000401:mortality / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D011960:Receptors, Estrogen / Q000032:analysis / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000032:analysis / Q000096:biosynthesis*; D046888:Tissue Array Analysis; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
keywords: Hormone receptors; Immunohistochemistry; Survival; Uterine sarcoma